scholarly journals Herpes simplex virus-infected squamous cell carcinoma: a case report

2022 ◽  
Vol 22 (1) ◽  
Author(s):  
Sarah H. Brown ◽  
Vanessa A. R. States ◽  
Abaseen K. Afghan ◽  
Gowri Satyanarayana

Abstract Background Herpes simplex virus (HSV)-1 is a highly prevalent, non-oncogenic virus that has higher morbidity in immunocompromised hosts. Its most common clinical manifestation is superficial ulceration of the integument or mucus membranes. Case presentation A 65-year-old woman with a history of acute myelogenous leukemia treated with allogenic peripheral blood stem cell transplant presented for resection of an ulcerated buccal squamous cell carcinoma. We report a case of HSV-1-infected malignant cells discovered on histopathological examination of the carcinoma specimen ultimately treated with valacyclovir. Conclusions HSV-1 is not considered an oncogenic virus itself but may increase risk of malignant progression. Cancer cells are vulnerable to superimposed viral infections, including HSV-1, which likely led to the findings in this case.

1988 ◽  
Vol 158 (4) ◽  
pp. 862-869 ◽  
Author(s):  
Raymond H. Kaufman ◽  
Jacob Bornstein ◽  
Ervin Adam ◽  
Joyce Burek ◽  
Barbara Tessin ◽  
...  

2009 ◽  
Vol 8 (3) ◽  
pp. 147-155
Author(s):  
Stuart McCaighy

AbstractThe unsatisfactory outcome of patients who receive intensive multimodality treatment for advanced squamous cell carcinoma of the head and neck (SCCHN) has motivated investigators to seek novel treatments to improve survival. Advances in molecular biology has led to the development of cancer gene therapy (CGT) and revived interest in viral vectors as a mechanism. SCCHN is an ideal model for CGT as disease remains locoregional and is amenable to injection of viruses. Adenovirus and Herpes Simplex Virus Type-1 (HSV) are the most studied Oncolytic Viruses (OVs). Both viruses have been shown to select and replicate in tumour cells and demonstrate anti-tumour effect in laboratory studies and clinical trials. Toxicity from OVs is minor and manageable. Different adenoviral mutants have been investigated with mixed responses. One vector, H101, has now been licensed after showing significant tumour regression in conjunction with chemotherapy. HSV has a larger capacity to carry genetic material and with the addition of the granulocyte–macrophage colony–stimulating factor, has the potential to stimulate an immune response systemically and at the site of disease. OVs are limited by the distribution of virus beyond injection site and by pre-existing or rapidly established immune response. Phase III studies are required.


Sign in / Sign up

Export Citation Format

Share Document